Drug maker Insys Therapeutics has enlisted investment banking firm Lazard to advise on its intentions “to explore strategic options and is in talks to divest its fentanyl sublingual spray Subsys, sending the company’s shares down 15% percent in after-hours trading, according to a report out of Reuters.
https://thefly.com/landingPageNews.php?id=2876473
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.